Efrat Makov Form 3 Anchiano Therapeutics / Efrat Makov ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Makov Efrat

(Last) (First) (Middle)

C/O ANCHIANO THERAPEUTICS LTD.

5 KIRYAT HAMADA ST., P.O. BOX 45032

(Street)

JERUSALEM L3 9777401

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2020

3. Issuer Name and Ticker or Trading Symbol
Anchiano Therapeutics Ltd. [ ANCN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock options	(1)	09/19/2028	Ordinary Shares	353	4.11(3)	D
Employee stock options	(2)	07/02/2029	Ordinary Shares	55,000	1.03	D

Explanation of Responses:

1. 1/4 of the options vest one year following the vesting commencement date of September 20, 2018, and 1/16 at the end of each calendar quarter thereafter, until fully vested.

2. 1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested.

3. The exercise price was converted from New Israeli Shekel ("NIS") 14.73 using the Bank of Israel representative rate known on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

	/s/ Efrat Makov	01/02/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.